Table 2.
Characteristics of operated patients
| Total n = 528 |
Dataset A N = 459 |
Dataset B N = 69 |
P value | |
|---|---|---|---|---|
| Age, n | 0.9722b | |||
| < 40 | 135 (26.57%) | 118 (25.71%) | 17 (24.64%) | |
| 40–69 | 367 (69.51%) | 318 (69.28%) | 49 (71.01%) | |
| ≥ 70 | 26 (4.92%) | 23 (5.01%) | 3 (4.35%) | |
| Menopausal Status | 0.793b | |||
| Premenopause | 316 (59.85%) | 276 (60.13%) | 40 (57.97%) | |
| Menopause | 212 (40.15%) | 183 (39.87%) | 29 (42.03%) | |
| Surgery, n | 528 | 0.6992b | ||
| SLN biopsy only | 242 (45.83%) | 212 (46.19%) | 30 (43.78%) | |
| ALND | 286 (54.17%) | 247 (53.81%) | 39 (56.52%) | |
| ALN Ultrasound, n | 0.0089 | |||
| LN Not reported | 273 (51.71%) | 249 (54.25%) | 24 (34.78%) | |
| LN Reported | 161 (30.49%) | 131 (28.54%) | 30 (43.48%) | |
| LN Metastasis suspected | 94 (17.80%) | 79 (17.21%) | 15 (21.74%) | |
| Neoadjuvant Chemotherapy | 0.0839b | |||
| Yes | 37 (7.01%) | 31 (6.75%) | 9 (13.04%) | |
| No | 491 (92.99%) | 428 (93.25%) | 60 (86.96%) | |
| Pathological results, n | 0.0011* | |||
| Benign | 168 (31.82%) | 158 (34.42%) | 10 (14.49%) | |
| Pre-malignant | 30 (5.68%) | 28 (6.10%) | 2 (2.90%) | |
| Malignant | 330 (62.50%) | 273 (59.48%) | 57 (82.61%) | |
| Molecular Subtypes | 0.5565 | |||
| Luminal A | 78 (23.64%) | 68 (24.91%) | 10 (17.54%) | |
| Luminal B | 160 (48.48%) | 132 (48.35%) | 28 (49.12%) | |
| HER2-enriched | 44 (13.33%) | 34 (12.45%) | 10 (17.54%) | |
| Tripple-Negative | 48 (14.55%) | 39 (14.29%) | 9 (15.77%) | |
| Histological Subtypes | 0.2340 | |||
| Invasive ductal carcinoma | 292 (88.48%) | 242 (88.64%) | 50 (87.72%) | |
| Invasive lobular carcinoma | 16 (4.85%) | 15 (5.50%) | 1 (1.75%) | |
| Other Invasive carcinoma | 22 (6.67%) | 16 (5.86%) | 6 (10.53%) | |
| Lymph Vascular Invasion | 0.4266b | |||
| Yes | 98 (29.70%) | 84 (30.77%) | 14 (24.56%) | |
| No | 232 (70.30%) | 189 (69.23%) | 43 (75.44%) | |
| T stage | 0.0656b | |||
| T0(DCIS) | 30 (8.33%) | 28 (9.30%) | 2 (3.39%) | |
| T1 | 184 (51.11%) | 155 (51.50%) | 29 (49.15%) | |
| T2 | 129 (35.84%) | 101 (33.55%) | 28 (47.46%) | |
| T3 | 17 (4.72%) | 17 (5.65%) | 0 (0) | |
| N stage | 0.0831b | |||
| N0 | 138 (41.82%) | 117 (42.86%) | 21 (36.84%) | |
| N1 | 103 (31.21%) | 77 (28.20%) | 26 (45.62%) | |
| N2 | 44 (13.33%) | 39 (14.29%) | 5 (8.77%) | |
| N3 | 45 (13.64%) | 40 (14.65%) | 5 (8.77%) | |
| ER | 0.5216b | |||
| Positive | 237 (71.82%) | 198 (72.53%) | 39 (68.42%) | |
| Negative | 93 (28.18%) | 75 (27.47%) | 18 (31.58%) | |
| PR | 0.7662b | |||
| Positive | 203 (61.52%) | 169 (61.90%) | 34 (59.65%) | |
| Negative | 127 (38.48%) | 104 (38.10%) | 23 (40.35%) | |
| HER-2 | 0.0521b | |||
| Positive | 95 (28.79%) | 81 (29.67%) | 14 (24.56%) | |
| Negative | 235 (71.21%) | 192 (70.33%) | 43 (75.44%) | |
| Ki67(%)a | 43.42 ± 23.92 | 43.25 ± 26.02 | 44.23 ± 25.67 |
Data are presented as n (%). Data were analyzed using the χ2 test unless otherwise specified. P values of less than 0.05 were considered statistically significant
SLN Sentinel lymph node, LN Lymph node, ALND Axillary lymph node dissection, DCIS Ductal carcinoma in situ, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2
aData are means ± SD
bFisher’s extract test